M Ventures

Netherlands · Venture Capital & Private Equity

M Ventures is the corporate venture capital fund of Merck KGaA, based in Darmstadt, Germany. Established in 2009, it manages a fund of around €600 million, focusing on early-stage investments in the biotechnology and technology sectors. The fund typically invests between €1 million and €5 million in companies from seed to Series B rounds, targeting areas such as healthcare drug development, life science tools, electronics, frontier technology, and sustainability. The mission of M Ventures is to support innovative companies that create solutions for challenging diseases and sustainability issues. The fund takes an active role in its portfolio companies, collaborating closely with entrepreneurs and co-investors to drive commercial success. Notable portfolio companies include ImmuneBridge, Tignis, Outrun Therapeutics, MemryX, Calypso Biotech, and beeOLED, which are developing advanced therapies and technologies across various fields.